Abstract: Quinazoline compounds which demonstrate antiproliferative activity, such as antitumor activity, processes of preparing these compounds, pharmaceutical compositions containing these compounds, and the use of these compounds. These compounds inhibit the growth and proliferation of the cells of higher organisms and microorganisms, such as bacteria, yeasts and fungi. Preferred quinazoline compounds are capable of inhibiting the enzyme thymidylate synthase. Effects derived from the inhibition of the enzyme thymidylate synthase include those discussed above.
Type:
Grant
Filed:
September 4, 1997
Date of Patent:
March 23, 1999
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Stephen E. Webber, Ted M. Bleckman, John Attard, Terrence R. Jones, Michael D. Varney
Abstract: The present invention relates to novel extracts of Piliostigma thonningii Schum. having antiviral action, the process for the preparation thereof, the therapeutical use thereof and formulations containing said extracts. These novel extracts are used in the treatment of pathologies of viral origin, such as herpetic, influenza and broncho-pulmonary diseases and they also proved to be active on HIV virus.
Type:
Grant
Filed:
July 13, 1994
Date of Patent:
June 3, 1997
Assignee:
Indena S.p.A.
Inventors:
Ezio Bombardelli, Paolo Morazzoni, Giuseppe Mustich
Abstract: An antiviral polysaccharide purified from an extract prepared by extracting Spirulina cells with hot water, having the following properties:(1) it comprises rhamnose, glucose, fructose, ribose, galactose, xylose, mannose, glucuronic acid and galacturonic acid;(2) it exhibits an absorption at 480 nm in phenolsulfuric acid reaction; and(3) it has a molecular weight of 250,000 to 300,000 Daltons as determined by gel filtration; and pharmaceuticals, food and feed, comprising said antiviral polysaccharide.
Type:
Grant
Filed:
July 8, 1994
Date of Patent:
December 17, 1996
Assignee:
Nippon Oil Co., Ltd.
Inventors:
Toshimitsu Hayashi, Kyoko Hayashi, Ichiro Kojima
Abstract: The present invention relates to purified extracts from Neem leaves. The extracts inhibit the adhesion of infectious cells and cancer cells to endothelial cells. The extracts also inhibit viruses, and malaria parasites in both the asexual and sexual forms. The invention also relates to a method of extraction, and pharmaceutical preparations containing the purified extracts.
Abstract: Compounds of the formula: ##STR1## are useful as anti-cancer, anti-obesity, anti-diabetic, anti-coronary agents, anti-aging agents, anti-hypolipidemic agents and anti-autoimmune agents.
Abstract: A non-specific therapeutic polyvalent vaccine for subcutaneous injection containing a minimum combination of a PPD (tuberculin vaccine), a rabies vaccine, and snake venom vaccine and preferably including at least a DTP vaccine in addition and optimally a mumps antigen vaccine and Dermatophytin vaccine in controlled levels, all such constituent vaccines being commercially available. The vaccine provides a broad-based stimulation or potentiation of the immuno-defense system of the patient and is useful for the symptomatic relief and/or mitigation of diseases of viral origin, such as Herpes Zoster, labialis and genitalis, various neuralgias, mumps, measles, viral hepatitis, psoriasis and severe acne, or of autoimmune origin, such as multiple sclerosis and arthritis.